Kezar Life Sciences (KZR) Announces Proposed Common Share Offering

Kezar Life Sciences, Inc. (NASDAQ: KZR) today announced that it intends to offer and sell shares of its common stock in an underwritten public offering. All of the common stock in the offering will be sold by Kezar. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or the actual size or terms of the offering.

Jefferies, Cowen and William Blair are acting as joint book-running managers for the offering. Kezar expects to grant the underwriters a 30-day option to purchase additional shares of common stock in the proposed offering of up to 15% of the aggregate number of shares of common stock being offered in the offering.

Kezar intends to use the net proceeds from the offering primarily to fund the research and development of its product candidates, acquire or license products or technologies that are complementary to its own, although Kezar has no current plans, commitments or agreements with respect to any acquisitions or licenses as of the date hereof, and for working capital and general corporate purposes.

You May Also Be Interested In

• DeFi Development Corp. plans $20M preferred stock offering
• Department of War adds Starshield AI's Grok to GenAI platform
• Hyper Bit Technologies closes $1.49M private placement